• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心力衰竭中的肥胖悖论:是时候向前迈进了。

THE OBESITY PARADOX IN HEART FAILURE: TIME TO MOVE FORWARD.

作者信息

Deswal Anita

机构信息

Houston, TX.

出版信息

Trans Am Clin Climatol Assoc. 2025;135:43-51.

PMID:40771616
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12323472/
Abstract

Obesity is a risk factor for incident heart failure (HF), linked to, but also independent of, coexisting comorbidities. The association of obesity is stronger for HF with preserved versus reduced ejection fraction. Further, obesity is associated with a higher risk of HF hospitalization in patients with HF. However, multiple studies in patients with prevalent HF have suggested that higher body mass index (BMI) is associated with lower mortality-the "obesity survival paradox." This paradox was also observed with preexisting obesity prior to the development of HF. These observations had complicated the case for the routine recommendation of weight loss in patients with obesity and HF. However, recent trials with anti-obesity medications are leading to a better understanding of the benefits of weight loss in HF and thus support a reevaluation of the obesity survival paradox in HF.

摘要

肥胖是新发心力衰竭(HF)的一个危险因素,与并存的合并症有关,但也独立于合并症。肥胖与射血分数保留型心力衰竭的关联比与射血分数降低型心力衰竭的关联更强。此外,肥胖与心力衰竭患者因心力衰竭住院的风险较高有关。然而,多项针对已患心力衰竭患者的研究表明,较高的体重指数(BMI)与较低的死亡率相关——即“肥胖生存悖论”。在心力衰竭发生之前就已存在肥胖的情况下也观察到了这一悖论。这些观察结果使肥胖和心力衰竭患者常规建议减重的情况变得复杂。然而,近期使用抗肥胖药物的试验正在使人们更好地理解减重对心力衰竭的益处,从而支持对心力衰竭中的肥胖生存悖论进行重新评估。

相似文献

1
THE OBESITY PARADOX IN HEART FAILURE: TIME TO MOVE FORWARD.心力衰竭中的肥胖悖论:是时候向前迈进了。
Trans Am Clin Climatol Assoc. 2025;135:43-51.
2
Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT Trial.体重指数、中心性肥胖和体重减轻对替尔泊肽治疗射血分数保留的心力衰竭(HFpEF)疗效的影响:SUMMIT试验
J Am Coll Cardiol. 2025 Jul 29;86(4):242-255. doi: 10.1016/j.jacc.2025.04.059.
3
Exploring the impact of metabolic comorbidities on epicardial adipose tissue in heart failure with preserved ejection fraction.探索代谢合并症对射血分数保留的心力衰竭患者心外膜脂肪组织的影响。
Cardiovasc Diabetol. 2025 Mar 22;24(1):134. doi: 10.1186/s12933-025-02688-7.
4
Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial.射血分数保留的心力衰竭患者中心性肥胖几乎普遍存在:PARAGON-HF试验
Eur Heart J. 2025 Jan 28. doi: 10.1093/eurheartj/ehaf057.
5
Association Between Cardiometabolic Comorbidity Burden and Outcomes in Heart Failure.心脏代谢合并症负担与心力衰竭预后之间的关联
J Am Heart Assoc. 2025 Feb 4;14(3):e036985. doi: 10.1161/JAHA.124.036985. Epub 2025 Jan 23.
6
Intentional weight loss in overweight and obese patients with heart failure: A systematic review.超重和肥胖心力衰竭患者的体重管理:系统评价。
Eur J Heart Fail. 2024 Sep;26(9):1907-1930. doi: 10.1002/ejhf.3270. Epub 2024 May 16.
7
Heart Failure and Obesity: The Latest Pandemic.心力衰竭与肥胖:最新的大流行病。
Prog Cardiovasc Dis. 2023 May-Jun;78:43-48. doi: 10.1016/j.pcad.2023.05.003. Epub 2023 May 24.
8
Obesity and Risk of Kidney Outcomes in Heart Failure With Preserved Ejection Fraction: A Participant-Level Pooled Analysis of 4 Contemporary Trials.射血分数保留的心力衰竭患者的肥胖与肾脏结局风险:4项当代试验的参与者水平汇总分析
JACC Heart Fail. 2025 Aug;13(8):102498. doi: 10.1016/j.jchf.2025.03.042. Epub 2025 Jun 9.
9
Body mass index, exercise capacity and functional status in chronic heart failure.慢性心力衰竭患者的体重指数、运动能力及功能状态
BMC Cardiovasc Disord. 2025 Jul 18;25(1):524. doi: 10.1186/s12872-025-04998-w.
10
Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.替尔泊肽10毫克和15毫克与司美格鲁肽2.4毫克治疗2型糖尿病患者肥胖和超重的间接比较疗效与安全性
Diabetes Obes Metab. 2025 Jun 19. doi: 10.1111/dom.16508.

本文引用的文献

1
Obesity and Severe Obesity Prevalence in Adults: United States, August 2021-August 2023.2021年8月至2023年8月美国成年人肥胖及重度肥胖患病率
NCHS Data Brief. 2024 Sep(508). doi: 10.15620/cdc/159281.
2
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.替尔泊肽用于射血分数保留的心力衰竭合并肥胖症
N Engl J Med. 2025 Jan 30;392(5):427-437. doi: 10.1056/NEJMoa2410027. Epub 2024 Nov 16.
3
HF STATS 2024: Heart Failure Epidemiology and Outcomes Statistics An Updated 2024 Report from the Heart Failure Society of America.《2024年心力衰竭统计数据:美国心力衰竭学会2024年更新报告》
J Card Fail. 2025 Jan;31(1):66-116. doi: 10.1016/j.cardfail.2024.07.001. Epub 2024 Sep 24.
4
Obesity and Weight Loss Strategies for Patients With Heart Failure.心力衰竭患者的肥胖与减肥策略
JACC Heart Fail. 2024 Sep;12(9):1509-1527. doi: 10.1016/j.jchf.2024.06.006. Epub 2024 Jul 31.
5
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.司美格鲁肽与安慰剂治疗射血分数保留的肥胖相关性心力衰竭患者的比较:STEP-HFpEF和STEP-HFpEF DM随机试验的汇总分析
Lancet. 2024 Apr 27;403(10437):1635-1648. doi: 10.1016/S0140-6736(24)00469-0. Epub 2024 Apr 7.
6
In patients with HFpEF and obesity, semaglutide increased weight loss and reduced symptoms and physical limitations at 52 wk.在 HFpEF 合并肥胖症患者中,司美格鲁肽可在 52 周时增加体重减轻,并减轻症状和身体活动受限。
Ann Intern Med. 2023 Dec;176(12):JC136. doi: 10.7326/J23-0101. Epub 2023 Dec 5.
7
Body mass index and survival in people with heart failure.体重指数与心力衰竭患者的生存。
Heart. 2023 Sep 28;109(20):1542-1549. doi: 10.1136/heartjnl-2023-322459.
8
Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox.体格测量指标与射血分数降低型心力衰竭不良结局:重新审视肥胖悖论。
Eur Heart J. 2023 Apr 1;44(13):1136-1153. doi: 10.1093/eurheartj/ehad083.
9
Updates on obesity and the obesity paradox in cardiovascular diseases.肥胖与心血管疾病中肥胖悖论的研究进展。
Prog Cardiovasc Dis. 2023 May-Jun;78:2-10. doi: 10.1016/j.pcad.2022.11.013. Epub 2022 Dec 5.
10
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.停用司美格鲁肽后的体重反弹和心脏代谢影响:STEP 1 试验延伸。
Diabetes Obes Metab. 2022 Aug;24(8):1553-1564. doi: 10.1111/dom.14725. Epub 2022 May 19.